Poland· PL-100181790

Torisel

A temsirolimus product containing temsirolimusum, registered in Poland by Pfizer Europe MA EEIG. The same ATC class is registered in 10 of our 19 countries.

ATC L01EG01

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedToriselATCL01EG01REGISTER NO.PL-100181790PACKS LISTED1CHECKEDSeptember 27, 2026

Where it is registered

Temsirolimus is registered in 10 of 19 countries.

Countries holding a registration under ATC L01EG01 (temsirolimus), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 5 of them publish a price we can compare per daily dose

Temsirolimus · ATC L01EG01

10 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Japan
  • Netherlands
  • Polandprice
  • United Kingdom
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

URPL (Poland)
Active substance
Temsirolimusum
Manufacturer
Pfizer Europe MA EEIG
Country
Poland (PL)
ATC code
L01EG01
ATC class
Temsirolimus
Defined daily dose
3.57 mg, P
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 1

  • gtin
    05909990080663

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

596 interactions on record for temsirolimus.

Graded by severity as the source publishes them — 168 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Temsirolimus · interactions on record

596 records

  • 168 severe
  • 419 moderate
  • 9 minor

Most severe, free to view

  • NeomycinA07AA01severe
  • StreptomycinA07AA04severe
  • Polymyxin BA07AA05severe
  • Amphotericin BA07AA07severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/f739e938-b2b5-49f2-b071-978ce5334df3
GET /v1/drugs/f739e938-b2b5-49f2-b071-978ce5334df3?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Koncentrat i rozpuszczalnik do sporządzania roztworu do infuzji",
  "source": "urpl",
  "strength": "30 mg",
  "packaging": "05909990080663 ¦ Rpz ¦ EU/1/07/424/001 ¦ 38571\n1 fiol. 1,2 ml koncentratu ¦ 1 fiol. 2,2 ml rozp.",
  "substance": "Temsirolimusum 25 mg/ml",
  "common_name": "Temsirolimusum",
  "pl_product_id": "100181790",
  "pozwolenie_nr": null,
  "auth_procedure": "CEN",
  "authorisation_validity": null
}

See everything about temsirolimus.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.